难治性高血压的诊断与管理
难治性高血压指改善生活方式并联合使用包括长效钙通道阻滞剂、肾素-血管紧张素系统阻断剂和利尿剂在内的至少三种降压药后血压仍高于目标值。诊断需确认治疗依从性、通过诊室外血压测量证实血压高于目标值并排除继发性高血压。管理要点包括生活方式干预、优化现有治疗方案(如单片复方制剂、最大耐受剂量),第四线治疗推荐螺内酯等盐皮质激素受体拮抗剂。
要点
- 诊断难治性高血压需确认依从性、诊室外血压升高并排除继发性病因。
- 优化治疗包括单片复方制剂和最大耐受剂量,根据年龄、 ethnicity、合并症调整方案。
- 第四线治疗推荐螺内酯,替代药物包括阿米洛利、多沙唑嗪等。
核心结论
- 难治性高血压的管理需综合生活方式干预、治疗方案优化和第四线药物选择。
研究设计与样本
- 综述性文章,基于PATHWAY-2试验和荟萃分析等证据总结诊断与管理策略。
主要发现
- PATHWAY-2试验和荟萃分析显示螺内酯作为第四线治疗有效。
- 正在研究的新方法包括选择性非甾体盐皮质激素受体拮抗剂(如finerenone、esaxerenone、ocedurenone)、选择性醛固酮合酶抑制剂(如baxdrostat)和双重内皮素拮抗剂aprocitentan。
关键数值与推荐
- 难治性高血压定义为改善生活方式并同时使用至少三种降压药(包括长效CCB、ACE抑制剂或ARB和利尿剂)后血压仍高于目标值。
- 诊断需确认治疗依从性、通过诊室外血压测量证实血压高于目标值并排除继发性高血压。
- 第四线治疗推荐螺内酯;替代药物包括阿米洛利、多沙唑嗪、依普利酮、可乐定和β受体阻滞剂。
临床怎么用
- 生活方式干预包括减少钠和酒精摄入、规律体育活动、减重和停用干扰血压控制的物质。
- 优化现有治疗包括使用单片复方制剂和最大耐受剂量,根据患者年龄、种族、合并症和药物相互作用风险调整方案。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Resistant hypertension is a condition where blood pressure levels remain elevated above target despite changes in lifestyle and concurrent use of at least three antihypertensive agents, including a long-acting calcium channel blocker (CCB), a blocker of the renin-angiotensin system (ACE inhibitor or angiotensin receptor blocker) and a diuretic. To be diagnosed as resistant hypertension, maintaining adherence to therapy is required along with confirmation of blood pressure levels above target by out-of-office blood pressure measurements and exclusion of secondary causes of hypertension. The key management points of this condition include lifestyle changes such as reduced sodium and alcohol intake, regular physical activity, weight loss and discontinuation of substances that can interfere with blood pressure control. It is also recommended that current treatment be rationalised, including single pill combination treatment where antihypertensive drugs should be provided at the maximum tolerated dose. It is further recommended that current drugs be replaced with a more appropriate and less difficult treatment regimen based on the patient's age, ethnicity, comorbidities and risk of drug-drug interactions. The fourth line of treatment for patients with resistant hypertension should include mineralocorticoid receptor antagonists such as spironolactone, as demonstrated in the PATHWAY-2 trial and meta-analyses. Alternatives to spironolactone include amiloride, doxazosin, eplerenone, clonidine and beta-blockers, as well as any other antihypertensive drugs not already in use. New approaches under research are selective non-steroidal mineralocorticoid receptor antagonists such as finerenone, esaxerenone and ocedurenone, selective aldosterone synthase inhibitors such as baxdrostat, and dual endothelin antagonist aprocitentan.
引用
- Camafort M, Kreutz R, Cho MC, et al. Diagnosis and management of resistant hypertension. Heart. 2024. PMID: 38135468. doi:10.1136/heartjnl-2022-321730
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。